This project will address the therapy of mesothelin expressing tumors by developing and testing engineered T cells with potent antitumor cytotoxicity. Mesothelin is a tumor-associated antigen that is frequently over expressed on mesothelioma, non-small cell lung cancer, pancreatic and ovarian cancers. Our strategy is the """"""""T-body"""""""" approach, which uses genetically reprogrammed, patient-derived lymphocytes transfected with a novel chimeric receptor that contains combinations of the signal transduction domains of 4-1BB (CD137), CD28, and CD3<;as well as anti-mesothelin scFv (anti-meso-CD28-41BB-Q. The central hypothesis that we wish to test is that insufficient numbers of CTL with adequate engraftment, persistence and effector function to self antigens have been used in previous trials of adoptive therapy for cancer. Presently, we are the only laboratory in the world that is actively testing lentiviral modified T cells in the clinic, and in that trial we have demonstrated safety and prolonged lentiviral gene transfer. The following three specific aims will test the hypothesis that engineered human T cells expressing an anti-mesothelin-CD28-41BB-<;chimeric receptor will have potent antitumor activity in vitro and in vivo by: (1) developing and optimizing the anti-meso scFv vector. The avidity and the cytosolic signaling modules will be optimized to obtain highly efficient lentiviral vectors that retarget T cells to specifically kill tumor cells that express mesothelin at low effector to target ratios in vitro;(2) carrying out in vitro experiments to optimize the effector functions of anti-mesothelin scFv CD28-41BB-?;T bodies. Experiments will determine optimal conditions for redirected T cell serial killing, cytokine production and proliferation, and compare this to natural MHC restricted CTLs;and (3) performing in vivo experiments in immunodeficient NOD/SCID/(32nu"""""""" mice xenografted with human tumors that express mesothelin. Here we will test the hypothesis that vectors with high affinity scFv receptors and 4-1BB and CD28 signaling modules will have the most potent anti-tumor effects. Finally, the engraftment, persistence and antitumor effects of chimeric T cells given by intravenous and intraperitoneal routes will be compared using bioluminescence imaging. In summary, we have assembled an outstanding team of basic and translational scientists to develop and test a universal T cell receptor to target some of the most common and drug resistant tumors. Lay Description. A common reason for failure of immunotherapy of epithelial tumors is that the immune system does not generate sufficient numbers of T cells to eradicate the tumor cells. It is now possible to use lentiviral vector technology to engineer T cells with potent and specific antitumor effects. In this project we will test engineered T cells that target mesothelin that is overexpressed on both uncommon tumors such as mesothelioma and a variety of commonly lethal tumors including pancreatic, ovarian and non-small cell lung carcinoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Yovandich, Jason L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Ruella, Marco; Klichinsky, Michael; Kenderian, Saad S et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov 7:1154-1167
Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2017) Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. Protein Cell 8:514-526
Hu, Biliang; Ren, Jiangtao; Luo, Yanping et al. (2017) Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. Cell Rep 20:3025-3033
Ren, Jiangtao; Liu, Xiaojun; Fang, Chongyun et al. (2017) Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res 23:2255-2266
Tchou, Julia; Zhao, Yangbing; Levine, Bruce L et al. (2017) Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunol Res 5:1152-1161
Ren, Jiangtao; Zhang, Xuhua; Liu, Xiaojun et al. (2017) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8:17002-17011
Ruella, M; Kenderian, S S; Shestova, O et al. (2017) Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31:246-248
Kawalekar, Omkar U; O'Connor, Roddy S; Fraietta, Joseph A et al. (2016) Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44:380-90
Fesnak, Andrew D; June, Carl H; Levine, Bruce L (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16:566-81
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90

Showing the most recent 10 out of 44 publications